Assessment Status | Assessment Process Complete |
HTA ID | 20061 |
Drug | Mogamulizumab |
Brand | Poteligeo® |
Indication | For the treatment of adult patients with mycosis fungoides or Sézary syndrome who have received at least one prior systemic therapy. |
Assessment Process | |
Rapid review commissioned | 21/12/2020 |
Rapid review completed | 21/01/2021 |
Rapid review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of mogamulizumab (Poteligeo®) compared with the current standard of care. |
Full pharmacoeconomic assessment commissioned by HSE | 27/01/2021 |
Pre-submission consultation with Applicant | 23/03/2021 |
Full submission received from Applicant | 07/10/2021 |
Preliminary review sent to Applicant | 22/02/2022 |
NCPE assessment re-commenced | 23/03/2022 |
Follow-up to preliminary review sent to Applicant | 07/04/2022 |
NCPE assessment re-commenced | 19/04/2022 |
Factual accuracy sent to applicant | 17/06/2022 |
NCPE assessment re-commenced | 24/06/2022 |
NCPE assessment completed | 09/08/2022 |
NCPE assessment outcome | The NCPE recommends that mogamulizumab (Poteligeo®) not be considered for reimbursement unless cost-effectiveness can be improved relative to existing treatments.* |
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.